Skip to main navigation

Contact Us
Global
- International
- Canada
- France
- Germany
- Italy
- Japan
- Netherlands
- Spain

About Amicus
- About Amicus
- Belief Statement
- Board of Directors
- Our Founding Legacy
- Senior Management Team
- Message from the President and CEO
Patient Advocacy
- Patient Advocacy
- Rare Stories
- Patient Advisory Boards
- Resources
- Expanded Access
Programs & Pipeline
- Programs & Pipeline
- Our Pipeline
- Fabry Disease
- Pompe Disease
- Batten Disease
- Additional Preclinical Programs
- Clinical Trials
- Global Research Center
Products
- Products & Services
- Galafold^®(migalastat)
- Pombiliti^® + Opfolda^®(cipaglucosidase alfa-atga) (miglustat)
- AMICUS ASSIST^®
Responsibility
- Responsibility
- Ethics & Compliance
- Global Medical Affairs
- Corporate Giving
- Healing Beyond Disease
- ESG Report
Investors & Media
- Investors & Media
- Investor Relations
- Corporate Governance
- Press Releases
- Events & Presentations
- Annual Reports and Proxies
- SEC Filings
- Stock Performance
- Analyst Consensus
- Investor FAQs
- Contact Us
- Sign Up for Email Alerts
Careers
- Careers
- Overview
- Search

Investors

Email Alert Registration

Email Alert Registration

Unsubscribe from all Amicus Therapeutics email alerts

* Indicates required field

Email Address

Leave this field blank

About Amicus

Patient Advocacy

Programs & Pipeline

Our Products

Responsibility

Investors & Media

Careers

Social Media
- Twitter
- YouTube
- LinkedIn

Copyright © 2024 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119

Cookies Statement
Terms of Use
Privacy Notice
Privacy Shield Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional